(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2009 (19.02.2009)

PCT

(10) International Publication Number
WO 2009/023540 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/22* (2006.01)

(21) International Application Number:
PCT/US2008/072561

(22) International Filing Date: 8 August 2008 (08.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/964,224	10 August 2007 (10.08.2007)	US
60/994,526	20 September 2007 (20.09.2007)	US
61/062,860	28 January 2008 (28.01.2008)	US
61/079,259	9 July 2008 (09.07.2008)	US

(71) Applicant *(for all designated States except US)*: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(71) Applicant and
(72) Inventor *(for all designated States except US)*: **REINHARDT, Joel, C.** [US/US]; 63 Moore Avenue, Mount Kisco, NY 10549 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MACDONALD, Lynn** [US/US]; 19 Gedney Way, White Plains, NY 10605 (US). **TORRES, Richard** [US/US]; 344 West 72nd Street, Apt. 7h, New York, NY 10023 (US). **MORRA, Marc, R.** [US/US]; 108 Foxton Court, Beacon Falls, CT 06403 (US). **MARTIN, Joel, H.** [US/US]; 244 Church Road, Putnam Valley, NY 10579 (US).

(74) Agent: **VALETA, Gregg**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN NERVE GROWTH FACTOR

(57) **Abstract:** A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, does not cross-react with neurotrophin-3 (NT-3), and binds human NGF with a KD of about 2 to about 10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from bums, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.

WO 2009/023540 A1